In pathological conditions such as CTSK deficiency or tumor-induced osteolysis, non-osteoclastic MMP-13 may potentially compensate for collagen degradation in bone, as evidenced by the consistent rate of collagen breakdown independent of MMP-13 (Delaissé et al., 2003). Here, MMP13 is linked to neoplasm.